AbbVie Inc (ABBV)vsSight Sciences Inc (SGHT)
ABBV
AbbVie Inc
$261.07
+3.99%
HEALTHCARE · Cap: $447.62B
SGHT
Sight Sciences Inc
$5.45
-3.26%
HEALTHCARE · Cap: $309.59M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 78865% more annual revenue ($62.82B vs $79.55M). ABBV leads profitability with a 5.8% profit margin vs -46.8%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
SGHT
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.1%
Fair Value
$146.57
Current Price
$261.07
$114.50 premium
Margin of Safety
+30.1%
Fair Value
$7.91
Current Price
$5.45
$2.46 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
No standout strengths identified
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -69.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : SGHT
Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : SGHT
The primary concerns for SGHT are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while SGHT is a turnaround play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.40 — expect wider price swings.
SGHT is growing revenue faster at 12.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 28/100) and 12.4% revenue growth. SGHT offers better value entry with a 30.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is a leading medical technology company dedicated to innovating the treatment of ocular diseases, particularly through advanced solutions for glaucoma management. With a strong focus on both surgical and non-surgical methods, the company boasts a diverse product portfolio complemented by a comprehensive intellectual property strategy. As the demand for minimally invasive ophthalmic therapies continues to grow, Sight Sciences is strategically positioned to capture market share and enhance patient outcomes. Its commitment to advancing eye care technology and optimizing its distribution network presents a valuable investment opportunity within the rapidly evolving healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?